Decitabine/cedazuridine (Inqovi)

Small molecule

Also known as ASTX727

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Myelodysplastic Syndromes

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (1)
EU
  • Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. Inaqovi in combination with venetoclax is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
Product first approved 2023EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Myelodysplastic Syndromes
Phase 2 (14)
Acute Myeloid Leukemia
NCT07153497 · National Cancer Institute (NCI)
2026-11-27 – 2030-04-26 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT04746235 · M.D. Anderson Cancer Center
2021-02-22 – 2028-10-31 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04857645 · Groupe Francophone des Myelodysplasies
2021-06-22 – 2025-04-22 · MDS, AML
What this study did
NCT06351306 · Columbia University
2024-04-01 – 2024-04-01 · Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT05201066 · Novartis Pharmaceuticals
2023-02-28 – 2028-02-14 · Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
What this study did
NCT04093570 · Taiho Oncology, Inc.
2019-09-30 – 2027-12-31 · Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT05960773 · National Cancer Institute (NCI)
2024-01-31 – 2029-07-01 · Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations, Early-stage BAP1-associated Malignancies
What this study did
NCT05007873 · M.D. Anderson Cancer Center
2021-10-21 – 2028-10-30 · Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive
What this study did
NCT06661915 · National Cancer Institute (NCI)
2025-08-14 – 2027-12-31 · Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm, Not Otherwise Specified, Polycythemia Vera, Primary Myelofibrosis, Secondary Myelofibrosis
What this study did
NCT05600894 · National Cancer Institute (NCI)
2023-06-27 – 2027-08-31 · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic/Myeloproliferative Neoplasm, Myeloproliferative Neoplasm
What this study did
NCT04872543 · Memorial Sloan Kettering Cancer Center
2021-04-29 – 2027-04 · Malignant Peripheral Nerve Sheath Tumors (MPNST)
What this study did
NCT04340843 · National Cancer Institute (NCI)
2020-09-08 – 2027-01-27 · Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
What this study did
NCT04878432 · Novartis Pharmaceuticals
2022-03-17 – 2024-09-01 · Myelodysplastic Syndrome (MDS)
What this study did
NCT06297629 · M.D. Anderson Cancer Center
2024-07-01 – 2024-07-11 · Allogeneic Stem Cell Transplantation
What this study did
Phase 1/2 (15)
Acute Myeloid Leukemia
NCT05010122 · M.D. Anderson Cancer Center
2021-07-08 – 2028-01-30 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05360160 · M.D. Anderson Cancer Center
2022-10-14 – 2026-12-01 · Acute Myeloid Leukemia
What this study did
NCT04817241 · National Cancer Institute (NCI)
2022-02-10 – 2026-11-05 · Acute Myeloid Leukemia
What this study did
NCT06113289 · M.D. Anderson Cancer Center
2024-02-08 – 2025-03-06 · Acute Myeloid Leukemia
What this study did
NCT02649790 · Karyopharm Therapeutics Inc
2016-01 – 2024-12-23 · Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
What this study did
NCT04013880 · Vanderbilt-Ingram Cancer Center
2019-08-27 – 2022-03-31 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
What this study did
Myelodysplastic Syndromes
NCT04742634 · Washington University School of Medicine
2022-05-12 – 2033-11-30 · Myelodysplastic Syndromes
What this study did
NCT06284460 · M.D. Anderson Cancer Center
2025-01-31 – 2027-12-01 · Pathway Mutant Myelodysplastic Syndromes, Myelodysplastic Neoplasm, Myeloproliferative Neoplasm
What this study did
NCT03502668 · Taiho Oncology, Inc.
2018-07-27 – 2026-01-13 · Myelodysplastic Syndromes
What this study did
NCT05918055 · National Cancer Institute (NCI)
2023-11-14 – 2025-03-12 · Myelodysplastic Syndromes
What this study did
Other / comorbidity
NCT07472322 · University of Wisconsin, Madison
2026-11 – 2031-05 · Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IV
What this study did
NCT04655755 · M.D. Anderson Cancer Center
2021-01-19 – 2028-07-20 · Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
What this study did
NCT04061421 · Michael Savona
2021-11-24 – 2027-12 · MDS/MPN
What this study did
Phase 1 (19)
Acute Myeloid Leukemia
NCT05396859 · OHSU Knight Cancer Institute
2022-10-28 – 2027-02-01 · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04155580 · Astex Pharmaceuticals, Inc.
2020-06-12 – 2022-01-14 · Acute Myeloid Leukemia
What this study did
Myelodysplastic Syndromes
NCT06484062 · National Cancer Institute (NCI)
2025-08-15 – 2028-06-01 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome/Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia
What this study did
NCT04953897 · Taiho Oncology, Inc.
2021-12-15 – 2026-12 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT04953910 · Taiho Oncology, Inc.
2022-12-23 – 2026-12 · Acute Myeloid Leukemia, Myelodysplastic Syndromes
What this study did
NCT04980404 · Massachusetts General Hospital
2021-09-17 – 2026-11 · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Stem Cell Leukemia
What this study did
NCT03906695 · Otsuka Pharmaceutical Co., Ltd.
2019-03-15 – 2026-01-31 · Lower-risk Myelodysplastic
What this study did
NCT03813186 · Astex Pharmaceuticals, Inc.
2018-11-08 – 2019-12-16 · Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT05178693 · Imperial College London
2022-04-25 – 2030-01-30 · Neuroendocrine Tumors
What this study did
NCT06802146 · Lachelle D. Weeks, MD, PhD
2025-02-07 – 2028-12-01 · Clonal Cytopenia of Undetermined Significance, Cytopenia
What this study did
NCT03922555 · Massachusetts General Hospital
2019-07-12 – 2028-08-01 · Neurological Cancer
What this study did
NCT06177171 · Varun Monga, MBBS
2024-02-07 – 2028-01-31 · BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene Mutation
What this study did
NCT05272384 · National Cancer Institute (NCI)
2022-11-03 – 2027-06-28 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma
What this study did
NCT05673200 · National Cancer Institute (NCI)
2023-09-25 – 2027-02-23 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT02998567 · Royal Marsden NHS Foundation Trust
2017-01-26 – 2026-09 · Non Small Cell Lung Cancer
What this study did
NCT06357858 · Case Comprehensive Cancer Center
2024-06-01 – 2026-02-28 · Recurrent Squamous Cell Carcinoma of the Head and Neck, Metastatic Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
What this study did
NCT03019003 · Massachusetts General Hospital
2017-03-20 – 2024-09-24 · Head and Neck Cancer
What this study did
NCT04134884 · Kathy Miller
2020-04-01 – 2024-03-14 · Metastatic Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Tumor
What this study did

Competitive landscape

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Decitabine / Cedazuridine (Inqovi): this drugApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race

Large race: only the 60 furthest-along competitors are listed; 70 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(24 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Decitabine/cedazuridine (Inqovi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
December 2026 (4)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT04953897 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT04953910 · CT.gov ↗
What to watch
Phase 1Clonal Cytopenia of Undetermined Significance, CytopeniaRecruiting
Est. primary completion 2026-12-01 · NCT06802146 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-01 · NCT05360160 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 1Neurological CancerRecruiting
Est. primary completion 2027-01-01 · NCT03922555 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Malignant Peripheral Nerve Sheath Tumors (MPNST)Recruiting
Est. primary completion 2027-04 · NCT04872543 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1Neuroendocrine TumorsRecruiting
Est. primary completion 2027-05-30 · NCT05178693 · CT.gov ↗
What to watch
June 2027 (1)
Phase 1Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma …Recruiting
Est. primary completion 2027-06-28 · NCT05272384 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1/2MDS/MPNRecruiting
Est. primary completion 2027-08 · NCT04061421 · CT.gov ↗
What to watch
Phase 2Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts …Active not recruiting
Est. primary completion 2027-08-31 · NCT05600894 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Acute Myeloid LeukemiaEnrolling by invitation
Est. primary completion 2027-12-31 · NCT04093570 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm, Essential Thrombocythemia …Recruiting
Est. primary completion 2027-12-31 · NCT06661915 · CT.gov ↗
What to watch
2028 (9)
January 2028 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT05010122 · CT.gov ↗
What to watch
Phase 1BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene MutationActive not recruiting
Est. primary completion 2028-01-31 · NCT06177171 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Myelodysplastic SyndromesActive not recruiting
Est. primary completion 2028-02-14 · NCT05201066 · CT.gov ↗
What to watch
June 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-06-01 · NCT06484062 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Mesothelioma, Malignant Mesothelioma (MM), Early-stage Mesothelioma, Subclinical Mesothelioma, BRCA1-Associated Protein-1 (BAP1) Mutations …Recruiting
Est. primary completion 2028-07-01 · NCT05960773 · CT.gov ↗
What to watch
Phase 1/2Chronic Myelomonocytic Leukemia, Myelodysplastic SyndromeActive not recruiting
Est. primary completion 2028-07-20 · NCT04655755 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia …Active not recruiting
Est. primary completion 2028-10-30 · NCT05007873 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-10-31 · NCT04746235 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06191978 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2030-04-26 · NCT07153497 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 1/2Merkel Cell Carcinoma, Merkel Cell Carcinoma, Stage III, Merkel Cell Carcinoma, Stage IVNot yet recruiting
Est. primary completion 2031-05 · NCT07472322 · CT.gov ↗
What to watch
2033 (1)
November 2033 (1)
Phase 1/2Myelodysplastic SyndromesRecruiting
Est. primary completion 2033-11-30 · NCT04742634 · CT.gov ↗
What to watch

See the full readout calendar ↗